Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05903794 · ClinicalTrials.gov registry record · Phase 1
A Study of EXG102-031 in Patients With wAMD (Everest)
A Phase 1 study of Neovascular (Wet) Age-related Macular Degeneration (nAMD), sponsored by Exegenesis Bio.
- Active
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 2
- Study locations
NCT05903794 is a Phase 1 study of Neovascular (Wet) Age-related Macular Degeneration (nAMD) that is active but no longer recruiting, run by Exegenesis Bio. The registered enrollment target is 12 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT05903794, a Phase 1 study of Neovascular (Wet) Age-related Macular Degeneration (nAMD), is active but no longer recruiting, sponsored by Exegenesis Bio.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 2
- Study locations
Study Summary
In neovascular (wet) age-related macular degeneration (nAMD), the macula, or the part of the eye that provides the clear, detailed central vision, is being affected by abnormal blood vessel growth and leakage. This leakage affects the vision over time and can lead to severe blurriness or blinding. EXG102-031 was made to block the extra vessel formation which would lead to less leakage affecting the vision. Before EXG102-031 can be tested for its efficacy (if it makes vision better), it must be tested to see if it is safely tolerated to confirm it can continue to be studied in more patients with nAMD.
Conditions Studied
Interventions
- BIOLOGICAL EXG102-031
Study Locations (2)
Nevada
- Sierra Eye Associates - Reno
Pennsylvania
- Erie Retina Research - Erie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2023-07-24 |
| Est. Completion | 2026-02-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05903794
The ClinicalTrials.gov registry entry for NCT05903794 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Exegenesis Bio, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neovascular (Wet) Age-related Macular Degeneration (nAMD) appearing as the primary indexed condition, and to 1 intervention - of which EXG102-031 is the first listed.
NCT05903794 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Nevada, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05903794 about?
NCT05903794 is a clinical study titled "A Study of EXG102-031 in Patients With wAMD (Everest)". In neovascular (wet) age-related macular degeneration (nAMD), the macula, or the part of the eye that provides the clear, detailed central vision, is being affected by abnormal blood vessel growth and leakage. This leakage affects the vision over time and can lead to severe blurriness or blinding. E...
What is the current status of trial NCT05903794?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2023-07-24. Estimated completion is 2026-02-28.
What conditions does trial NCT05903794 study?
This clinical trial studies the following conditions: Neovascular (Wet) Age-related Macular Degeneration (nAMD).
What interventions are being tested in trial NCT05903794?
The interventions under investigation include: EXG102-031 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05903794?
This trial is sponsored by Exegenesis Bio, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05903794 being conducted?
This trial has 2 study locations across Nevada, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.